Repletion of Ergothioneine in Patients With Kidney Failure
ConditionEsrd
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorStanford University
About this trial
Dialysis removes potentially harmful chemicals from the blood but can also remove potentially valuable chemicals. One potentially valuable chemical called ergothioneine, which comes from the diet, is low in the blood of people receiving dialysis. For this research study, the investigators hope to learn how well a daily ergothioneine supplement will replenish the levels in the blood of people with kidney failure.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
kidney failure receiving hemodialysis or peritoneal dialysis
Disqualifiers
blood transfusion within 90 days
taking supplements which contain ergothioneine
Trial design
Design model
Parallel
Treatments tested in this trial
Ergothioneine
Dietary supplementParticipants will receive ergothioneine capsule daily for 12 weeks.
Placebo
Other interventionParticipants will receive placebo capsule daily for 12 weeks.
Treatment groups
28 Participants
are divided into 2 treatment groupsGroup A: ErgothioneineExperimental treatment 1 intervention
Group B: PlaceboPlacebo comparator 1 intervention
Trial outcomes
Primary outcomes
1
erythrocyte levels of ergothioneine
ergothioneine levels will be measured in whole blood
Time frame
weeks 1, 2, 4, 8, and 12 (while taking ergothioneine or placebo); and weeks 16 and 20 (after stopping ergothioneine or placebo)Secondary outcomes
1
plasma levels of ergothioneine
ergothioneine levels will be measured in plasma
Time frame
weeks 1, 2, 4, 8, and 12 (while taking ergothioneine or placebo); and weeks 16 and 20 (after stopping ergothioneine or placebo)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov